Equities

10X Genomics Inc

10X Genomics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)13.29
  • Today's Change-0.03 / -0.23%
  • Shares traded1.63m
  • 1 Year change-68.96%
  • Beta1.8180
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy5
Outperform3
Hold10
Sell1
Strong Sell0

Share price forecast in USD

The 15 analysts offering 12 month price targets for 10X Genomics Inc have a median target of 20.00, with a high estimate of 30.00 and a low estimate of 14.00. The median estimate represents a 50.49% increase from the last price of 13.29.
High125.7%30.00
Med50.5%20.00
Low5.3%14.00

Earnings history & estimates in USD

On Oct 29, 2024, 10X Genomics Inc reported 3rd quarter 2024 losses of -0.300 per share. This result exceeded the -0.34 consensus loss of the 17 analysts covering the company and exceeded last year's 3rd quarter results by 62.03%.
The next earnings announcement is expected on Feb 13, 2025.
Average growth rate+17.10%
10X Genomics Inc reported annual 2023 losses of -2.18 per share on Feb 15, 2024.
Average growth rate-176.48%
More ▼

Revenue history & estimates in USD

10x Genomics, Inc. had 3rd quarter 2024 revenues of 151.65m. This missed the 158.63m consensus estimate of the 15 analysts following the company. This was 12.93% above the prior year's 3rd quarter results.
Average growth rate+1.00%
10x Genomics, Inc. had revenues for the full year 2023 of 618.73m. This was 19.81% above the prior year's results.
Average growth rate+27.69%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.